New Delhi, Dec. 3 -- Keeping their uptrend intact for the second session, shares of Sun Pharma Advanced Research Company (SPARC) soared another 11.5% in Wednesday's session, December 3, hitting a six-month high of Rs.179.50 apiece in an otherwise falling market.

In the previous session, the shares were locked at the 20% upper circuit limit after the company announced that the US District Court for the District of Columbia had granted summary judgment in its favor regarding the issuance of a Priority Review Voucher (PRV) associated with the approval of Sezaby.

Sezaby is a benzyl alcohol- and propylene glycol-free formulation of phenobarbital sodium powder for injection. It was approved by the US FDA for the treatment of neonatal seizures...